Playback speed
10 seconds
SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Have We Learned From CVOTs in T2DM? Is MACE Independent of Glucose Lowering?
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
271 views
January 15, 2021
Login to view comments.
Click here to Login